Thurston Springer Miller Herd & Titak Inc. boosted its position in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 11.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,246 shares of the biotechnology company's stock after purchasing an additional 325 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.'s holdings in Axon Enterprise were worth $1,707,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of AXON. Bleakley Financial Group LLC lifted its stake in Axon Enterprise by 1.3% during the fourth quarter. Bleakley Financial Group LLC now owns 1,527 shares of the biotechnology company's stock valued at $908,000 after purchasing an additional 20 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in shares of Axon Enterprise by 2.7% during the 4th quarter. Venturi Wealth Management LLC now owns 802 shares of the biotechnology company's stock worth $477,000 after acquiring an additional 21 shares in the last quarter. Beacon Pointe Advisors LLC grew its holdings in shares of Axon Enterprise by 2.6% in the 4th quarter. Beacon Pointe Advisors LLC now owns 864 shares of the biotechnology company's stock worth $513,000 after acquiring an additional 22 shares during the last quarter. Burns Matteson Capital Management LLC raised its position in shares of Axon Enterprise by 3.4% during the fourth quarter. Burns Matteson Capital Management LLC now owns 757 shares of the biotechnology company's stock worth $450,000 after purchasing an additional 25 shares during the period. Finally, Transcend Capital Advisors LLC raised its position in shares of Axon Enterprise by 3.6% during the fourth quarter. Transcend Capital Advisors LLC now owns 726 shares of the biotechnology company's stock worth $431,000 after purchasing an additional 25 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on AXON. Bank of America lifted their price target on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research note on Wednesday. Barclays raised their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Needham & Company LLC boosted their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Northcoast Research lowered shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. Finally, Craig Hallum cut shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, Axon Enterprise has an average rating of "Moderate Buy" and an average price target of $699.55.
View Our Latest Research Report on Axon Enterprise
Axon Enterprise Stock Up 0.4%
AXON stock traded up $3.49 during midday trading on Friday, reaching $791.85. The company had a trading volume of 443,537 shares, compared to its average volume of 731,575. The company has a 50 day moving average of $638.88 and a two-hundred day moving average of $615.19. The company has a market capitalization of $61.65 billion, a P/E ratio of 204.61, a PEG ratio of 5.17 and a beta of 1.24. Axon Enterprise, Inc. has a 1 year low of $278.24 and a 1 year high of $798.16. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The business had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. During the same period in the prior year, the business posted $1.15 earnings per share. Axon Enterprise's revenue for the quarter was up 31.3% compared to the same quarter last year. On average, equities research analysts expect that Axon Enterprise, Inc. will post 5.8 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the sale, the chief executive officer now directly owns 3,063,982 shares in the company, valued at $1,657,583,622.18. The trade was a 0.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Brittany Bagley sold 3,400 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $700.00, for a total value of $2,380,000.00. Following the completion of the transaction, the chief financial officer now owns 131,833 shares in the company, valued at $92,283,100. This represents a 2.51% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 43,969 shares of company stock valued at $29,909,594 in the last three months. Insiders own 4.40% of the company's stock.
Axon Enterprise Company Profile
(
Free Report)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Further Reading

Before you consider Axon Enterprise, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axon Enterprise wasn't on the list.
While Axon Enterprise currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.